Scholar Rock (NASDAQ:SRRK) Given Buy Rating at HC Wainwright

Scholar Rock (NASDAQ:SRRK)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $58.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 24.62% from the company’s current price.

SRRK has been the subject of a number of other reports. UBS Group began coverage on Scholar Rock in a report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price target for the company. Barclays boosted their target price on shares of Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. BMO Capital Markets reiterated an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research note on Friday, November 14th. Wolfe Research initiated coverage on Scholar Rock in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 target price for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $51.14.

Scholar Rock Stock Up 7.0%

NASDAQ SRRK traded up $3.06 during trading hours on Tuesday, reaching $46.54. 1,091,774 shares of the company traded hands, compared to its average volume of 994,116. The stock has a market capitalization of $4.75 billion, a PE ratio of -14.77 and a beta of 0.70. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock has a 12 month low of $22.71 and a 12 month high of $49.82. The company has a 50 day moving average of $45.32 and a two-hundred day moving average of $38.99.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). During the same period last year, the company earned ($0.64) EPS. As a group, equities analysts expect that Scholar Rock will post -2.42 earnings per share for the current year.

Insider Transactions at Scholar Rock

In other Scholar Rock news, insider Mo Qatanani sold 8,484 shares of Scholar Rock stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $47.07, for a total value of $399,341.88. Following the transaction, the insider owned 98,445 shares in the company, valued at approximately $4,633,806.15. The trade was a 7.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Caryn Parlavecchio sold 9,035 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total value of $420,398.55. Following the sale, the insider directly owned 169,087 shares in the company, valued at $7,867,618.11. This trade represents a 5.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 344,932 shares of company stock worth $15,371,225 over the last 90 days. 13.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Scholar Rock

Several institutional investors have recently made changes to their positions in SRRK. Orbis Allan Gray Ltd increased its stake in Scholar Rock by 1,034.5% in the 4th quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock valued at $151,044,000 after buying an additional 3,126,677 shares during the period. Wellington Management Group LLP raised its holdings in shares of Scholar Rock by 124.5% during the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after acquiring an additional 2,521,022 shares in the last quarter. Holocene Advisors LP acquired a new stake in Scholar Rock during the third quarter valued at $91,670,000. Norges Bank acquired a new position in Scholar Rock in the 4th quarter worth about $91,603,000. Finally, Siren L.L.C. raised its stake in shares of Scholar Rock by 17.0% during the 4th quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock worth $476,842,000 after purchasing an additional 1,575,008 shares in the last quarter. 91.08% of the stock is currently owned by institutional investors and hedge funds.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).